Epigenetic alterations, including gain or loss of DNA methylation, are a hallmark of nearly every malignancy. Changes in DNA methylation can impact expression of cancer-related genes including apoptosis regulators and tumor suppressors. Because such epigenetic changes are reversible, they are being aggressively investigated as potential therapeutic targets. Here we use the E-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) to determine the timing and patterns of aberrant DNA methylation, and to investigate the mechanisms that lead to aberrant DNA methylation. We show that CLL cells from E-TCL1 mice at various stages recapitulate epigenetic alterations seen in human CLL. Aberrant methylation of promoter sequences is observed as early as 3 months of age in these animals, well before disease onset. Abnormally methylated promoter regions include binding sites for the transcription factor FOXD3. We show that loss of Foxd3 expression due to an NF-B p50/p50:HDAC1 repressor complex occurs in TCL1-positive B cells before methylation. Therefore, specific transcriptional repression is an early event leading to epigenetic silencing of target genes in murine and human CLL. These results provide strong rationale for the development of strategies to target NF-B components in CLL and potentially other B-cell malignancies.
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CLL ͉ DNA methylation ͉ epigenetics ͉ FOXD3 E pigenetic alterations in cancer receive great attention since their contributions to tumor development and progression have now been documented (1) . Major questions in the field relate to formation of global patterns of epigenetic alterations, the mechanisms that lead to epigenetic changes and the role of target genes in healthy tissues (2) . Epigenetics, or the inheritance of gene expression patterns through mechanisms that do not change the DNA sequence, were initially investigated by measurement of DNA methylation occurring at cytosine residues. However, it is also clear that additional epigenetic factors such as histone tail modifications or small RNAs cooperate in the epigenetic regulation of genes (3, 4) . DNA methylation in mammals occurs predominantly at cytosine residues, creating a 5-methylcytosine. The covalent addition of a methyl group to cytosine is stable from fixation processes and therefore allows high-throughput genome-wide or gene-specific quantification of DNA methylation on archived samples (5) .
DNA methylation abnormalities, especially gain of methylation in normally unmethylated promoter or other regulatory regions (hypermethylation) or loss of methylation in normally methylated repetitive sequences (hypomethylation), have been described for almost all human tumor types as well as tumors from animal models, suggesting a general mechanism in cancer that leads to aberrant DNA methylation. However, there is evidence that individual patterns of aberrant methylation are tumor-type specific and non-random, thus arguing for additional tissue-specific mechanisms (6) . Based on in vitro studies, several groups have put forward mechanisms of methylation specificity, postulating the recruitment of DNA methyltransferases (DNMTs) to target sites by oncogenes or sequence-specific methylation events (7) . However in vivo experiments have been unable to confirm these hypotheses.
Similarly unclear is the timing of aberrant DNA methylation events. There is evidence that epigenetic alterations could precede the initiation of tumorigenesis as exemplified by the recent discoveries of epimutations in MLH1 or MSH2 predisposing to colorectal cancer (8) , or the loss of DNMT1 activity in mouse models developing T-cell lymphoma (9) . However, these examples seem to be more the exception than the rule, leaving room for more general and still undiscovered mechanisms. Evidence for DNA methylation as an early event in transformation comes from studies of clinical samples in lung and colon cancer, where DNA methylation changes were detected in early preneoplastic lesions (10) .
Chronic lymphocytic leukemia (CLL) is characterized by gradually increasing levels of malignant B cells in the bone marrow, lymphoid organs and circulation that are resistant to the normal process of apoptosis. Recently, a transgenic mouse model of CLL was generated by introducing the human TCL1 gene under control of a B cell-specific Ig promoter and E enhancer (11) . TCL1 transgenic mice develop a monoclonal B-cell lymphocytosis that is very similar to human CLL in immunophenotypic and clinical features as well as response to fludarabine, a commonly used agent in this disease (12) . In this study, we investigated epigenetic alterations in this CLL mouse model at various times before development of disease. We demonstrate that DNA methylation changes occur early in disease development and recapitulate alterations seen in human CLL. Furthermore, our studies implicate silencing of transcription factor FOXD3 as a key event early in leukemogenesis in both mouse and human CLL.
Results
Disease-Specific DNA Methylation in E-TCL1 CLL Progression Recapitulates Epigenetic Alterations of Human CLL. Human CLL has been characterized as having multiple epigenetic defects that include abnormal methylation and silencing of genes. One oncogene, TCL1, is generally over-expressed in CLL and is associated with poor response to therapy (13) . The E-TCL1 transgenic mouse model of CLL shows characteristics similar to the human disease, with an initial expansion of non-clonal B lymphocytes at approximately 3 months followed by progression to a mature B-cell leukemia at 9-11 months (11) . Due to the similarities of human CLL and E-TCL1 murine leukemia, we hypothesized that aberrant epigenetic changes might also occur in the E-TCL1 mice and that the timing of such changes may provide valuable information both on CLL biology and on early targets for therapeutic intervention.
Genome-wide CpG hypermethylation was therefore evaluated in this model using restriction landmark genomic scanning [RLGS (14) ]. Cells obtained from spleens from E-TCL1 mice at 11-14 months, the age of leukemia onset, were compared to cells from spleens of age-matched wild-type (WT) mice. After eliminating 522 polymorphic fragments and 6 age-dependent methylation events, a total of 1,491 RLGS fragments were scored. An overall increase in DNA methylation was found in the spleen cells from E-TCL1 mice with symptomatic disease, ranging from 2.5% to 5.5% of all evaluated RLGS fragments. These frequencies of promoter methylation are comparable to the frequencies previously reported for human CLL (2.5-8.1%) which was significantly higher than age matched normal B cells (15) . (17) and myc-induced lymphoma (18) (Fig. 1C ).
Early and Accumulated DNA Hypermethylation in E-TCL1 CLL Progression. Next we investigated the frequency of altered DNA methylation in E-TCL1 mice at different time points before development of CLL. We found that methylation increased over time in E-TCL1 mice relative to WT animals, from 0.4%, 0.6%, 1.2%, and 1.9%, at 3, 5, 7, and 9 months respectively, to 3.9% in mice with advanced CLL (Fig. 2A) . Similar results were also obtained from CD19-selected B cells from E-TCL1 mice (0.4%, 1.0%, and 1.8% at 1, 5, and 7 months, respectively, and 4.1% in mice with advanced CLL; Table S1 ). Only minor age-dependent changes were found in the control mice, indicating that the increased frequency of DNA methylation is due to tumor-specific events (Fig. 2 A) . MassARRAY analysis was then performed to validate early aberrant DNA methylation in E-TCL1 B cells. Consistent with the RLGS data, Sox3, EphA7, Pcdh10, and Gpc6 were found to be methylated in CD19-positive B cells from E-TCL1 mice starting at 5 months of age; Dlx1 and Id4 were only found to be methylated in mice with advanced disease as defined by elevated lymphocyte counts and/or palpable spleen (Fig. 2B) . The repression of genes such as Sox3 and Gpc6 as determined by real-time RT-PCR correlated with the extent of increased DNA methylation detected in E-TCL1 mice (Fig. 2C) . Additionally, GPC6 expression was reactivated in the B-lymphoblastic lymphoma Raji cell line and the WaC3CD5 CLL-like cell line by 5-aza-2Ј-deoxycytidine (5-aza-dC) ( Fig. 2D  and E) , confirming the key role of methylation in silencing these genes.
Consistent with the increased aberrant DNA hypermethylation, elevated protein expression of the de novo DNA methyltransferases DNMT3A and DNMT3B, but not the maintenance methyltransferase DNMT1, was also observed in E-TCL1 mouse B-lymphocytes over time (Fig. S1 ). However, this observation does not explain the targeted aberrant DNA methylation that occurs both in mouse and human CLL. While targeted DNA methylation has been demonstrated to lead to transcriptional silencing, as shown for Myc-induced transcriptional repression through recruitment of DNMTs (19) , a growing body of evidence also supports that methylation-mediated silencing can occur following transcriptional repression (7, 20, 21) . We therefore searched for differences in predicted transcription factor-binding sites within promoter regions (Ϫ2 kb to ϩ1 kb) of methylated genes as compared to unmethylated genes. Using the Match program (22) , the FOXD3 binding site (5Ј-A[AT]T[AG]TTTGTTT-3Ј) was found as the most significantly over-represented sequence (Fig. S2 A and B , P ϭ 0.007). To validate the relevance of this site in B cells, chromatin immunoprecipitation (ChIP) was then performed to confirm the binding of FOXD3 within the predicted promoter regions in normal B cells. Of the 10 predicted targets in the methylated group that were tested, 9 showed FOXD3 binding by ChIP. In contrast, only 1 of the 10 unmethylated genes with a predicted FOXD3 binding sequence exhibited FOXD3 binding (Fig. 3A) .
Early Loss of Transcription Activators in E-TCL1 Mice. As described in Table S1 , Foxd3 was identified by RLGS to be methylated early in CLL progression in E-TCL1 mice. Indeed, Foxd3 methylation and down-regulation of FOXD3 expression was detected both in CLL patient cells relative to normal cells, and in E-TCL1 mice starting from 1-month-old mice relative to age-matched WT controls (Figs. 1A and 3 B and C) . Putative FOXD3 target genes including EphA7, Fign, and Phf2 also showed decreased expression in 1-month-old E-TCL1 mice (Fig. 3 D and E) . We hypothesized that this decreased expression is due to the loss of binding of FOXD3 within the promoter region. This hypothesis is supported by the transcription activator function of FOXD3, demonstrated by the increased promoter activity of both Dlx1 and EphA7 promoter luciferase constructs in Raji B cells with enforced FOXD3 expression (Fig.  4A) . Consistent with these luciferase results, increased endogenous DLX1 and EPHA7 gene expression occurred in FOXD3-expressing Raji B cells following treatment with the hypomethylating agent 5-aza-dC. Because both Dlx1 and EphA7 are densely methylated in the Raji cell line, demethylation via 5-aza-dC treatment permits binding of FOXD3 and subsequent reactivation of DLX1 and EPHA7 (Fig. 4 B and C) .
To test the effect of FOXD3 reduction on putative target genes, we used an shRNA approach. Because no B-cell lines without Foxd3 DNA methylation could be found, the FOXD3-positive Jurkat T cell line was used for these experiments. While most of the methylated genes found in CLL cells are also methylated in Jurkat T cells, DLX1 and PHF2 were found to be expressed in these cells. Interestingly, transfection of FOXD3 shRNA resulted in the silencing and methylation of both DLX1 and PHF2 following 17 days of culture (Fig. 4D) . Similar results were also observed in the FOXD3 shRNA-transfected K562 chronic myelogenous leukemia cells (Fig. S3) . Collectively, these data demonstrate that Foxd3 is silenced transcriptionally at a very early time point before development of disease and leads to silencing of many target genes dependent upon it for promoter activation.
FOXD3 Is Silenced by TCL1 Through a NF-B p50:HDAC1 Repressor
Complex. Silencing of Foxd3 was first observed in 1-month-old E-TCL1 mouse B cells, which is earlier than the occurrence of DNA methylation within the Foxd3 promoter noted at 3 months of age. This observation suggests that enforced TCL1 expression in B cells may directly contribute to FOXD3 transcriptional silencing. Consistent with this hypothesis, down-regulation of endogenous Foxd3 (Fig. 5A ) and decreased FOXD3 promoter activity (Fig. 5B) was detected in EBV-immortalized human PBL lines expressing exogenous TCL1. We therefore interrogated mouse and human Foxd3 promoters for transcription factor binding sites that could be regulated by signaling pathways relevant to TCL1 and to CLL pathogenesis. We identified a highly conserved putative NF-B binding site in both the mouse and human FOXD3 proximal promoters (Fig. 5B) , prompting an investigation of the role for NF-B in the regulation of FOXD3. Luciferase reporter assays in control or TCL1-expressing PBL lines indicated that FOXD3 promoter activity was significantly repressed by a combination of TCL1 and NF-B p50 subunit expression (Fig. 5C ). Repeated electrophoretic mobility shift assays (EMSA) demonstrate stronger binding of NF-B in extracts from CLL CD19ϩ selected cells compared with normal B cells, and the subsequent in vitro binding of p50 but not p65 to the FOXD3 promoter (Fig. 6A) . To identify other members of this DNA-binding complex, we performed EMSAs using antibodies to HDAC1 and HDAC3 based on their known role in FOXD3 repression or as part of other NF-B co-repressor complexes (23, 24) . The results shown in Figure 6A demonstrate that HDAC1 appears to be part of this repressor complex. ChIP assays further confirm that p50 and HDAC1, but not HDAC3 or p65, are bound to the FOXD3 promoter in CD19ϩ lymphocytes from both CLL patients and 1-month-old E-TCL1 mice (Fig.  6B) . In tolerant CD4
ϩ T-cells, it has been shown that the NF-B p50 subunit is over-expressed in the nuclear fraction and represses transcription of IL-2 cytokine (25). We therefore tested whether similar silencing of FOXD3 may occur in CLL cells. We demonstrate that nuclear but not cytoplasmic extracts of CLL contain higher p50 levels than normal B cells (Fig. 6C) . This was also observed in the isolated B cells from 1-month-old E-TCL1 mice (Fig. 6D) . TCL1 is reported to directly interact with AKT and enhance its nuclear expression (26) . This, coupled with the fact that phosphorylated AKT is enriched in the nucleus of CLL cells (Fig. 6C) , led us to hypothesize that a similar association of TCL1 with the NF-B p50 subunit also exists. Indeed, by forward and reverse immunoprecipitation, we demonstrated that TCL1 is directly associated with the NF-B p50 subunit in CLL cells but not in normal B cells (Fig. 6E) . Together, these results suggest transcriptional silencing of the NF-B p50:HDAC1 co-repressor complex might be involved in the CLL development.
Discussion
In this study, we use extensive cross-species epigenetic analyses to identify a mechanism by which early transcriptional silencing events in the development of CLL occurs as a consequence of TCL1 over-expression. Specifically, we identify the embryonic stem cell gene FOXD3 as 1 of the targets that is silenced early in B-cell transformation and precedes a cascade of gene silencing events detectable in mature CLL cells. Interestingly, we find that aberrant TCL1 expression leads to FOXD3 silencing through an NF-B p50:HDAC1-mediated corepressor complex. This unique co-repressor complex in TCL1-expressing B cells also is associated with increased nuclear p50 protein expression. Furthermore, in CLL cells but not normal B cells, we were able to demonstrate a direct interaction between TCL1 protein and the NF-B p50 subunit. This abnormal p50:TCL1 association and subsequent forma- tion of a p50:HDAC1 co-repressor complex provides a target for CLL therapy.
The E-TCL1 mouse studies described here demonstrate that transcriptional silencing represents an early event that is followed later by specific gene promoter methylation. While individual steps in this cascade of events need further investigation, a model has been proposed in colon and breast cancer where chromatin remodeling during the initial phases of gene silencing occurs before the DNA methylation (7, 20, 21) . Our model demonstrates the direct contribution of the TCL1 oncogene in the transcriptional silencing of the transcription factor Foxd3 by an NF-B p50:HDAC1 co-repressor complex. This subsequently triggers epigenetic silencing of downstream targets as a secondary event, leading to stable gene repression. Moreover, the fact that many Foxd3 target genes are also transcription factors implies a chain reaction, which may explain the accumulated number of hypermethylated genes in the E-TCL1 transgenic mouse, and potentially in human CLL. This process may be favored by the de novo methyltransferases DNMT3A and 3B. The timing of specific gene methylation in the E-TCL1 transgenic mouse is variable, and likely reflects differential promoter regulation by Foxd3 as well as the alteration of other contributing gene regulators in E-TCL1 mice. Nonetheless, our studies in this CLL model demonstrate that transcriptional silencing of genes early and late in transformation occurs before development of DNA promoter methylation.
To date, the presence of Foxd3 in normal mature B cells has not been reported and its function is uncharacterized. Foxd3 is a member of forkhead-box (FOX) family transcription factors characterized by a monomeric DNA binding domain for nuclear localization and transcriptional regulation (27) (28) (29) (30) . No studies have related either TCL1 or NF-B co-repressor complexes to the silencing of Foxd3. Recruited HDAC1 by NF-B p50/p50 homodimer forming the co-repressor complex, however, has been identified (23, 31) . NF-B repressor complex mediated transcriptional silencing has also been suggested to protect normal hepatocytes from TNF-␣ mediated apoptosis as a consequence of chronic inflammation (32) . We therefore hypothesize that this co-repressor complex could provide a similar survival advantage for TCL1 over-expressing lymphocytes. Future studies examining the role of this NF-B co-repressor complex and Foxd3 silencing in transformation of CLL as well as other malignancies are warranted.
Our study also emphasizes the critical role of NF-B in early epigenetic gene silencing of murine and human TCL1-positive CLL. A recent in vitro study suggests that TCL1 induces NF-B activity by forming a complex of TCL1/NF-B/CREB binding protein/p300 (33) . Here we demonstrate that, in human CLL cells, TCL1 and p50 directly associate in the nucleus, similar to the interaction previously observed with TCL1 and AKT (26) . With AKT, studies show that TCL1 both enhances activity of the kinase and also its nuclear translocation. Given that TCL1 was not identified in the p50:HDAC1 co-repressor complex, a selective subcellular localization role of TCL1 is a more likely mechanism that is currently under investigation in our laboratory. Given the importance of both co-repressor (data herein) and activating (34, 35) NF-B complexes in the pathogenesis of CLL, there is strong rationale for the early introduction of agents that target the NF-B pathway. In particular, small molecules derived to specifically inhibit the initiating p50:HDAC1 corepressor complex would be of great interest for early use in the treatment of asymptomatic CLL to prevent development of the full disease phenotype.
Methodology Mouse and Human Sample Preparation and Gene Expression Assays.
C3H/B6 (Jackson Laboratories) and TCL1 transgenic mouse spleen CD19ϩ B cells were isolated by magnetic-activated cell sorting beads (Miltenyi Biotec). All animal experiments were performed under protocols approved by the Ohio State University Institutional Laboratory Animal Care and Use Committee. Human peripheral blood B cells were Rosette-Sep separated (Stem Cell Technologies), sampling was performed according to IRB approved protocols. Isolated high-molecular weight genomic DNA was used for RLGS, COBRA and MassARRAY analysis (Sequenom) as previously described (15) . The construct of pJ6-Foxd3 was a kindly gift from R. Hromas. Foxd3 shRNA (Origene) transfected cells were selected by puromycin for 10 days. Cells were collected in 7 days after selection. Primer sequences used in gene expression assays are listed in Table S2 .
Immunoprecipitation and Electrophoretic Mobility Shift Assays
(EMSA). Co-immunoprecipitation (Co-IP) was performed by using 500 g B-cell nuclear extract following manufacturer's instructions (ebioscience) using TCL1 and p50 antibodies (Santa Cruz Biotechnologies). Chromatin immunoprecipitaion (ChIP) was performed as described previously (36) , the Ct values from IgG and FOXD3 pull-down were subtracted by the number obtained from 10ϫ diluted input DNA. The relative pull-down of FOXD3 was then normalized by the subtracted Ct value of IgG (set as 1.0). EMSA was performed as previously described (37) with following modifications. The probe sequence was designed based on the putative NF-B binding sequence (gggactttcg) within FOXD3 promoter. Oligonucleotides were labeled with [␣-32 P]dCTP using the Nick Translation System (Invitrogen). The free probe was removed by purification in G50 Sephadex spin columns. The binding reaction was conducted at room temperature for 20 min with 5 g nuclear extract and 20,000 dpm radiolabelled oligonucleotide probe. For supershift assay, 1 g antibody was added to the nuclear extract 15 min before addition of probe.
Cluster Analysis and Statistical Analysis. Hierarchical cluster analysis of samples was performed by applying phi-correlation (38) similarity metric with compact linkage method. All of the experiments were performed 3 times or more for the statistical analysis. Comparisons of 2 groups were performed by using non parametric Wilcox on rank sum test (39) and 2-tailed Student t test. Trend in methylation over time was evaluated by the Jonckheere-Terpstra test (44) . Proportions between groups were compared using Fisher's exact test. All of the analyses were performed by R 2.5.1 statistical program (http://www.r-project.org/). Error bars were developed by using mean Ϯ standard error of the mean (s.e.m.) or by mean Ϯ standard deviation (s.d.) of respective data.
